tci Part B Insider - 2004 Issue 13

Drug Reimbursement: FDA Approves Two New Cancer Drugs

Use J9999 to bill for Avastin and Erbitux,  but document carefullyMartha Stewart may be going to prison because she bet against ImClone's new cancer drug Erbitux, but careful coding and documentation can keep you out of trouble with billing for this drug. Erbitux is one of two new colorectal cancer drugs that just won Food and Drug Administration approval. The other one, Genetech's Avastin, aims to treat first-line, or previously untreated, colon or rectal cancer. By contrast, Erbitux is designed to treat patients with EGFR-expressing or metastatic colorectal cancer, and particularly ones who are intolerant to...

To read the full article, sign in and subscribe to tci Part B Insider.


Keep pace with evolving Medicare regulations with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI’s Part B Insider will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, the fee schedule, OIG target areas, and more.

  • Current newsletters added each month
  • Fully searchable archives - over 4800 articles
  • ALL years/issues back to 2003 organized by year and issue
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information pages link back to related articles

This feature is currently unavailable for online purchase. For more information, please call 801-770-4203 or Contact Us.

demo
request yours today
 subscribe
start today
 newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.